Does the media favor KRYS or RARE?

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 6 mentions for Krystal Biotech. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Krystal Biotech's score of 0.45 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RGC or RARE?

Ultragenyx Pharmaceutical has a consensus target price of $59.56, suggesting a potential upside of 104.61%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ultragenyx Pharmaceutical 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.82

Which has better valuation and earnings, RGC or RARE?

Regencell Bioscience has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Ultragenyx Pharmaceutical $673M 4.26 -$575M -$6.11 N/A

Does the media refer more to RGC or RARE?

In the previous week, Regencell Bioscience had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 17 mentions for Regencell Bioscience and 9 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Regencell Bioscience's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or CYTK?

In the previous week, Ultragenyx Pharmaceutical and Ultragenyx Pharmaceutical both had 9 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Cytokinetics' score of 0.96 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABVX or RARE?

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 2 mentions for Abivax. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Abivax's score of 0.31 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor QGEN or RARE?

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Qiagen. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 3 mentions for Qiagen. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Qiagen's score of 0.37 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$29.11 +0.35 (+1.22%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$29.12 +0.00 (+0.02%)

As of 06/24/2026 05:43 PM Eastern

Compare

RARE vs. KRYS, RGC, CYTK, ABVX, and QGEN

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? MarketBeat compares Ultragenyx Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ultragenyx Pharmaceutical include Krystal Biotech (KRYS), Regencell Bioscience (RGC), Cytokinetics (CYTK), Abivax (ABVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 6 mentions for Krystal Biotech. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Krystal Biotech's score of 0.45 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.34	$204.83M	$7.48	46.47
Ultragenyx Pharmaceutical	$673M	4.26	-$575M	-$6.11	N/A

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Krystal Biotech's return on equity of 19.25% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Krystal Biotech currently has a consensus price target of $340.56, suggesting a potential downside of 2.04%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 104.61%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Krystal Biotech beats Ultragenyx Pharmaceutical on 10 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Ultragenyx Pharmaceutical has a consensus target price of $59.56, suggesting a potential upside of 104.61%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Regencell Bioscience's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Regencell Bioscience had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 17 mentions for Regencell Bioscience and 9 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Regencell Bioscience's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Ultragenyx Pharmaceutical	$673M	4.26	-$575M	-$6.11	N/A

Summary

Ultragenyx Pharmaceutical beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Cytokinetics	-784.02%	N/A	-52.86%

Ultragenyx Pharmaceutical has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.26	-$575M	-$6.11	N/A
Cytokinetics	$88.04M	114.76	-$784.96M	-$6.84	N/A

Ultragenyx Pharmaceutical presently has a consensus price target of $59.56, suggesting a potential upside of 104.61%. Cytokinetics has a consensus price target of $100.20, suggesting a potential upside of 23.40%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Ultragenyx Pharmaceutical and Ultragenyx Pharmaceutical both had 9 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Cytokinetics' score of 0.96 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Abivax?

Abivax (NASDAQ:ABVX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Abivax presently has a consensus target price of $130.08, indicating a potential upside of 40.61%. Ultragenyx Pharmaceutical has a consensus target price of $59.56, indicating a potential upside of 104.61%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

47.9% of Abivax shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Abivax's return on equity of -99.02% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Abivax has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Abivax is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Ultragenyx Pharmaceutical	$673M	4.26	-$575M	-$6.11	N/A

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 2 mentions for Abivax. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Abivax's score of 0.31 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Abivax on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Qiagen?

Qiagen (NYSE:QGEN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Qiagen has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.82	$424.88M	$1.91	20.29
Ultragenyx Pharmaceutical	$673M	4.26	-$575M	-$6.11	N/A

Qiagen currently has a consensus target price of $44.71, indicating a potential upside of 15.38%. Ultragenyx Pharmaceutical has a consensus target price of $59.56, indicating a potential upside of 104.61%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.46
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Qiagen has a net margin of 19.16% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Qiagen's return on equity of 14.40% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Qiagen. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 3 mentions for Qiagen. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Qiagen's score of 0.37 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Summary

Qiagen beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.83B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.76	20.50	25.37	23.96
Price / Sales	4.26	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-35.07	8.26	10.76	6.41
Net Income	-$575M	$23.91M	$3.56B	$337.14M
7 Day Performance	6.09%	2.12%	0.99%	-1.06%
1 Month Performance	24.45%	2.40%	0.79%	0.49%
1 Year Performance	-22.23%	57.09%	30.25%	28.43%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.4908 of 5 stars	$29.11 +1.2%	$59.56 +104.6%	-21.7%	$2.83B	$673M	N/A	1,371
KRYS Krystal Biotech	2.6537 of 5 stars	$324.75 +2.1%	$324.11 -0.2%	+142.0%	$9.37B	$389.13M	43.42	210
RGC Regencell Bioscience	0.5211 of 5 stars	$17.09 -9.2%	N/A	-62.7%	$9.31B	N/A	N/A	10	Gap Down
CYTK Cytokinetics	3.5076 of 5 stars	$71.38 +1.8%	$99.30 +39.1%	+143.1%	$8.73B	$88.04M	N/A	250	Analyst Forecast Insider Trade
ABVX Abivax	3.1737 of 5 stars	$98.26 +1.8%	$130.08 +32.4%	+1,291.1%	$7.70B	N/A	N/A	61	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. KRYS, RGC, CYTK, ABVX, and QGEN

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Summary

How does Ultragenyx Pharmaceutical compare to Regencell Bioscience?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Summary

How does Ultragenyx Pharmaceutical compare to Abivax?

Summary

How does Ultragenyx Pharmaceutical compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. KRYS, RGC, CYTK, ABVX, and QGEN

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Does the media favor KRYS or RARE?

Which has preferable earnings & valuation, KRYS or RARE?

Which has more volatility & risk, KRYS or RARE?

Do institutionals & insiders have more ownership in KRYS or RARE?

Is KRYS or RARE more profitable?

Do analysts prefer KRYS or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Regencell Bioscience?

Do analysts recommend RGC or RARE?

Which has more risk & volatility, RGC or RARE?

Is RGC or RARE more profitable?

Do insiders & institutionals hold more shares of RGC or RARE?

Does the media refer more to RGC or RARE?

Which has better valuation and earnings, RGC or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Is RARE or CYTK more profitable?

Which has higher earnings & valuation, RARE or CYTK?

Do analysts recommend RARE or CYTK?

Does the media refer more to RARE or CYTK?

Which has more risk and volatility, RARE or CYTK?

Do insiders and institutionals hold more shares of RARE or CYTK?

Summary

How does Ultragenyx Pharmaceutical compare to Abivax?

Do analysts recommend ABVX or RARE?

Do institutionals & insiders believe in ABVX or RARE?

Which has more volatility and risk, ABVX or RARE?

Is ABVX or RARE more profitable?

Which has better earnings and valuation, ABVX or RARE?

Does the media prefer ABVX or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Qiagen?

Which has preferable earnings & valuation, QGEN or RARE?

Do analysts recommend QGEN or RARE?

Is QGEN or RARE more profitable?

Do insiders and institutionals believe in QGEN or RARE?

Does the media favor QGEN or RARE?

Which has more volatility & risk, QGEN or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools